HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment

• Published in: Cancer research (Chicago, Ill.) Vol. 84; no. 2; pp. 276 - 290
• Main Authors: Jacobs, Curteisha, Shah, Sakhi, Lu, Wen-Cheng, Ray, Haimanti, Wang, John, Hockaden, Natasha, Sandusky, George, Nephew, Kenneth P, Lu, Xin, Cao, Sha, Carpenter, Richard L
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 16.01.2024
• Subjects: Breast Cancer; Breast Neoplasms - pathology; Cancer Immunology; CD8-Positive T-Lymphocytes - metabolism; Cell Line, Tumor; Chemokine CCL5 - genetics; Chemokine CCL5 - metabolism; Computational Methods; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Female; Gene Regulation; Heat Shock Transcription Factors - genetics; Humans; Immunology; Transcription Factors - genetics; Transcription Factors - metabolism; Translational Research; Tumor Microenvironment
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-23-0902

Heat shock factor 1 (HSF1) is a stress-responsive transcription factor that promotes cancer cell malignancy. To provide a better understanding of the biological processes regulated by HSF1, here we developed an HSF1 activity signature (HAS) and found that it was negatively associated with antitumor immune cells in breast tumors. Knockdown of HSF1 decreased breast tumor size and caused an influx of several antitumor immune cells, most notably CD8+ T cells. Depletion of CD8+ T cells rescued the reduction in growth of HSF1-deficient tumors, suggesting HSF1 prevents CD8+ T-cell influx to avoid immune-mediated tumor killing. HSF1 suppressed expression of CCL5, a chemokine for CD8+ T cells, and upregulation of CCL5 upon HSF1 loss significantly contributed to the recruitment of CD8+ T cells. These findings indicate that HSF1 suppresses antitumor immune activity by reducing CCL5 to limit CD8+ T-cell homing to breast tumors and prevent immune-mediated destruction, which has implications for the lack of success of immune modulatory therapies in breast cancer. The stress-responsive transcription factor HSF1 reduces CD8+ T-cell infiltration in breast tumors to prevent immune-mediated killing, indicating that cellular stress responses affect tumor-immune interactions and that targeting HSF1 could improve immunotherapies.